原创力文档- 1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
- 2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
- 4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
- 5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传，每下载1次， 网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
百济神州科技有限公司 (BeiGene)
百济神州科技有限公司(BeiGene)
创建药物发现和开发的新成功模式
Creating new models for success in drug discovery and
development
BeiGene is a Chinese life sciences biotechnology company based in Beijing that is focused on
discovering and developing innovative oncology drugs that will address unmet medical needs in
cancers that are prevalent in China and the Asia-Pacific region.
BeiGene has excellent research and management team with many years of academic and deep
industry experience in the U.S. BeiGene is founded by four exceptional leaders, John Oyler, Wang
Xiaodong, Peter Ho and Pearl Huang with rich drug research and development experience and
superior business management capabilities. John Oyler obtained MBA from Stanford and served in
McKinsey Company, was former President orCEO of Telephia, Genta, Galenea and former Founder
CEO of BioDuro (700-person integrated research CRO in Beijing). Dr. Xiaodong Wang is the
Member of US National Academy of Sciences (新中国培养出来的第一位获此殊荣的科学家), Founder of
Joyant Pharmaceuticals (venture capital-backed oncology biotech in US); Howard Hughes
Investigator, Distinguished Chair of Biomedical Sciences and Professor of Biochemistry at University
of Texas-Southwestern; Director architect of 700 person National Institute of Biological Sciences in
Beijing (NIBS). Peter Ho obtained MD PhD (Pharmacology) from Yale University School of
Medicine, and then worked at US Food and Drug Administration , National Cancer Institute, the US
Public Health Service, was Former Medical Director at Novartis Pharmaceuticals, Former Oncology
Therapeutic Area Head at DuPont Pharmaceuticals, Former SVP of Oncology CEDD at
GlaxoSmithKline and Former VP of Oncology Development at Johnson Johnson. He was responsible
f
文档评论（0）